Kim Jinnam, Kim Changhyup, Lee Jung Ah, Lee Se Ju, Lee Ki Hyun, Kim Jung Ho, Ahn Jin Young, Jeong Su Jin, Ku Nam Su, Yeom Joon-Sup, Song Young Goo, Choi Jun Yong
Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Vaccines (Basel). 2023 Apr 1;11(4):784. doi: 10.3390/vaccines11040784.
This study investigated the immunogenicity of, and reactogenicity to, the ChAdOx1 nCoV-19 vaccine according to pre-existing adenovirus immunity. Individuals scheduled for COVID-19 vaccination were prospectively enrolled in a tertiary hospital with 2400 beds from March 2020 onwards. Pre-existing adenovirus immunity data was obtained before ChAdOx1 nCoV-19 vaccination. A total of 68 adult patients administered two doses of the ChAdOx1 nCoV-19 vaccine were enrolled. Pre-existing adenovirus immunity was identified in 49 patients (72.1%), but not in the remaining 19 patients (27.9%). The geometric mean titer of S-specific IgG antibodies was statistically higher in individuals without pre-existing adenovirus immunity at several time points: before the second ChAdOx1 nCoV-19 dose (56.4 (36.6-125.0) vs. 51.0 (17.9-122.3), = 0.024), 2-3 weeks after the second ChAdOx1 nCoV-19 dose (629.5 (451.5-926.5) vs. 555.0 (287.3-926.0), = 0.049), and 3 months after the second ChAdOx1 nCoV-19 dose (274.5 (160.5-655.3) vs. 176.0 (94.3-255.3), = 0.033). In the absence of pre-existing adenovirus immunity, systemic events were observed with higher frequency, especially chills (73.7% vs. 31.9%, = 0.002). In conclusion, individuals without pre-existing adenovirus immunity showed a higher immune response to ChAdOx1 nCoV-19 vaccination and a higher frequency of reactogenicity to ChAdOx1 nCoV-19 vaccination was observed.
本研究根据既往腺病毒免疫情况，调查了ChAdOx1 nCoV-19疫苗的免疫原性和反应原性。自2020年3月起，将计划接种COVID-19疫苗的个体前瞻性纳入一家拥有2400张床位的三级医院。在接种ChAdOx1 nCoV-19疫苗前获取既往腺病毒免疫数据。共纳入68例接受两剂ChAdOx1 nCoV-19疫苗的成年患者。49例患者（72.1%）存在既往腺病毒免疫，其余19例患者（27.9%）则不存在。在几个时间点，无既往腺病毒免疫的个体中S特异性IgG抗体的几何平均滴度在统计学上更高：在第二剂ChAdOx1 nCoV-19疫苗接种前（56.4（36.6 - 125.0）对51.0（17.9 - 122.3），P = 0.024）、第二剂ChAdOx1 nCoV-19疫苗接种后2 - 3周（629.5（451.5 - 926.5）对555.0（287.3 - 926.0），P = 0.049）以及第二剂ChAdOx1 nCoV-19疫苗接种后3个月（274.5（160.5 - 655.3）对176.0（94.3 - 255.3），P = 0.033）。在无既往腺病毒免疫的情况下，全身反应的发生率更高，尤其是寒战（73.7%对31.9%，P = 0.002）。总之，无既往腺病毒免疫的个体对ChAdOx1 nCoV-19疫苗表现出更高的免疫反应，并且观察到对ChAdOx1 nCoV-19疫苗的反应原性频率更高。
